Long-term followup of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation

Arthritis and Rheumatism

Volumn 52, Issue 8, 2005, Pages 2272-2276

  Teng, Y K O ^a   Verburg, R J ^a   Sont, J K ^a   Van Den Hout, W B ^a   Breedveld, F C ^a   Van Laar, J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; PREDNISONE;

ADULT; ALOPECIA; ARTHRITIS IMPACT MEASUREMENT SCALES; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; EUROPEAN QUALITY OF LIFE QUESTIONNAIRE; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH STATUS; HUMAN; LIFE EXPECTANCY; MALE; MORTALITY; NAUSEA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SHORT FORM 36; TREATMENT OUTCOME; VOMITING; WELLBEING;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEALTH STATUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE;

EID: 23644451346     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21219     Document Type: Article

References (19)

1. Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum 2001;44:2746-9.
2. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.
3. Verburg RJ, Toes RE, Fibbe WE, Breedveld FC, van Laar JM. High dose chemotherapy and autologous hematopoietic stem cell transplantation for rheumatoid arthritis: a review. Hum Immunol 2002;63:627-37.
4. Snowden JA, Passweg J, Moore JJ, Milliken S, Cannell P, van Laar J, et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol 2004;31:482-8.
5. Van der Heijde DM, van't Hof MA, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:538-41.
6. Verburg RJ, Kruize AA, van den Hoogen FH, Fibbe WE, Petersen EJ, Preijers F, et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy. Arthritis Rheum 2001;44:754-60.
7. Verburg RJ, Sont JK, Vliet Vlieland TP, Landewe RB, Boers M, Kievit J, et al. High dose chemotherapy followed by autologous peripheral blood stem cell transplantation or conventional pharmacological treatment for refractory rheumatoid arthritis? A Markov decision analysis. J Rheumatol 2001;28:719-27.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
9. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
10. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
11. Taal E, Jacobs JW, Seydel ER, Wiegman O, Rasker JJ. Evaluation of the Dutch Arthritis Impact Measurement Scales (DUTCH-AIMS) in patients with rheumatoid arthritis. Br J Rheumatol 1989;28:487-91.
12. Taal E, Seydel ER, Jacobs JW, Wiegman O, Rasker JJ. [The Dutch Arthritis Impact Measurement Scales (DUTCH-AIMS): assessment of physical and psychosocial aspects of health in rheumatoid arthritis], Gedrag Gezondheid 1989;17:69-74. In Dutch.
13. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21: 271-92.
14. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72.
15. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-9.
16. Verburg RJ, Sont JK, van Laar JM. Reduction of joint damage in severe rheumatoid arthritis by high-dose chemotherapy and autologous stem cell transplantation. Arthritis Rheum 2005;52:421-4.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
18. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20: 557-60.
19. Uhlig T, Smedstad LM, Vaglum P, Mourn T, Gerard N, Kvien TK. The course of rheumatoid arthritis and predictors of psychological, physical and radiographie outcome after 5 years of follow-up. Rheumatology (Oxford) 2000;39:732-41.